Sarcoma  >>  Sulanda (surufatinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sulanda (surufatinib) / Hutchmed
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed
1/2
13
US
Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine
Hutchmed, HUTCHMED Limited
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
04/23
04/23
NCT04579757: Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
135
US
Surufatinib and Tislelizumab _ Part 1, HMPL-012, sulfatinib, BGB-A317, Surufatinib and Tislelizumab _ Part 2
Hutchmed, BeiGene
Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
04/24
06/24
NCT05494580: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Recruiting
1/2
38
RoW
Pamiparib, Poly (ADP-ribose) polymerase (PARP) inhibitor, Surufatinib, Tyrosine Kinase Inhibitor
Sun Yat-sen University, Hutchmed
Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma, Primary Peritoneal Cancer
08/24
08/25

Download Options